High levels of C-reactive protein are associated with an increased risk of ovarian cancer: Results from the Ovarian Cancer Cohort Consortium
File(s) with restricted access are under embargo until 2020-08-28
AuthorPeres, Lauren C.; Mallen, Adrianne R.; Townsend, Mary K.; Poole, Elizabeth M.; Trabert, Britton; Allen, Naomi E.; Arslan, Alan A.; Dossus, Laure; Fortner, Renee T.; Gram, Inger T.; Hartge, Patricia; Idahl, Annika; Kaaks, Rudolf; Kvaskoff, Marina; Magliocco, Anthony M.; Merritt, Melissa A.; Quirós, Ramón; Tjonneland, Anne; Trichopoulou, Antonia; Tumino, Rosario; van Gils, Carla H.; Visvanathan, Kala; Wentzensen, Nicolas; Zeleniuch-Jacquotte, Anne; Tworoger, Shelley S.
Growing epidemiologic evidence supports chronic inflammation as a mechanism of ovarian carcinogenesis. An association between a circulating marker of inflammation, C-reactive protein (CRP), and ovarian cancer risk has been consistently observed, yet, potential heterogeneity of this association by tumor and patient characteristics has not been adequately explored. In this study, we pooled data from case–control studies nested within six cohorts in the Ovarian Cancer Cohort Consortium (OC3) to examine the association between CRP and epithelial ovarian cancer risk overall, by histologic subtype and by participant characteristics. CRP concentrations were measured from prediagnosis serum or plasma in 1,091 cases and 1,951 controls. Multivariable conditional logistic regression was used to estimate ORs and 95% confidence intervals (CI). When CRP was evaluated using tertiles, no associations with ovarian cancer risk were observed. A 67% increased ovarian cancer risk was found for women with CRP concentrations >10 mg/L compared with <1 mg/L (OR = 1.67; 95% CI = 1.12–2.48). A CRP concentration >10 mg/L was positively associated with risk of mucinous (OR = 9.67; 95% CI = 1.10–84.80) and endometrioid carcinoma (OR = 3.41; 95% CI = 1.07–10.92), and suggestively positive, although not statistically significant, for serous (OR = 1.43; 95% CI = 0.82–2.49) and clear cell carcinoma (OR = 2.05; 95% CI = 0.36–11.57; Pheterogeneity = 0.20). Heterogeneity was observed with oral contraceptive use (Pinteraction = 0.03), where the increased risk was present only among ever users (OR = 3.24; 95% CI = 1.62–6.47). This study adds to the existing evidence that CRP plays a role in ovarian carcinogenesis and suggests that inflammation may be particularly implicated in the etiology of endometrioid and mucinous carcinoma.